IPHA News and Press, Innate Pharma S.A. From 11/03/23

Positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome selected for oral presentation Preliminary monotherapy lacutamab Phase 1b clinical data and pre-clinical combinability data in patients with per...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. Jefferies London Healthcare Co...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2024 financial calendar: March 21, 2024: Publication of 2023 financial statements May 14, 2024: Publication of revenue for 1Q2024 May 23, 2024:...

Sanofi’s ongoing SAR’579/IPH6101 Phase 1/2 trial in hematologic malignancies selected for oral presentation Presentations under the AstraZeneca collaboration include an IPH5201 early lung cancer Trial in Progress poster and monalizumab SCCHN updates Innate Pharma...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)...

2023-10-05 06:28:54 ET More on Innate Pharma Innate Pharma S.A. (IPHA) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Innate Pharma Historical earnings data for Innate Pharma Financial information for Innate Pharma For further...

Phase 2 TELLOMAK trial fully recruited, final data expected Q4 2023 Phase 1b PTCL trial awaiting futility interim analysis, preliminary data expected Q4 2023 US FDA places lacutamab IND on partial clinical hold for new patient enrollment following one unexpected severe adv...

Efficacy results, analyzed according to updated lymph node involvement classification, confirm clinical activity and favorable safety profile of lacutamab in advanced Mycosis Fungoides Updated global ORR of 42.9% in heavily pretreated KIR3DL2-expressing patients with Mycosis F...

2023-09-14 11:54:09 ET Innate Pharma S.A. (IPHA) Q2 2023 Earnings Conference Call September 14, 2023, 08:00 AM ET Company Participants Henry Wheeler - VP, IR & Communication Mondher Mahjoubi - CEO Joyson Karakunnel - Interim Chief Medical Officer Yannis M...

2023-09-14 03:17:18 ET More on Innate Pharma Seeking Alpha’s Quant Rating on Innate Pharma Historical earnings data for Innate Pharma Financial information for Innate Pharma For further details see: Innate Pharma GAAP EPS of €0.02, revenue o...